Data Sheet (Cat.No.T10223)

TargetMol
A DRUG SCREENING EXPERT

ABT-100

Chemical Properties



CAS No.:	450839-40-4
Formula:	C27H19F3N4O3
Molecular Weight:	504.46
Appearance:	N/A
Storage:	0-4℃ for short term (days to weeks), or -20℃ for long term (months).

Biological Description

Description	ABT-100 is a potent, highly selective, and orally active farnesyl transferase inhibitor with broad-spectrum antitumor activity.
Targets(IC_{50})	Others: None
In vitro	ABT-100 (0.1-100 nM; 7 days; EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells) treatment shows dose-dependent growth inhibition of human cancer cell lines. It also inhibits colony formation at concentrations comparable with which ABT-100 inhibits anchorage-dependent growth. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis.
In vivo	ABT-100 (6.25-12.5 mg/kg/day; subcutaneous injection; daily; for 21 days; C.B-17 scid male mice) treatment regresses EJ-1 tumors in mice.
Cell Research	Cell Line: EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells Concentration: 0.1-100 nM Incubation Time: 7 days
Animal Research	Animal Model: C.B-17 scid male mice with EJ-1 cells Dosage: 6.25 mg/kg/day, 12.5 mg/kg/day Administration: Subcutaneous injection; daily; for 21 days

Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.982 mL	9.912 mL	19.823 mL
5 mM	0.396 mL	1.982 mL	3.965 mL
10 mM	0.198 mL	0.991 mL	1.982 mL
50 mM	0.04 mL	0.198 mL	0.396 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 ℃ for 6 months; - 20 ℃ for 1 month. Please use it as soon as possible.

Reference

1. Ferguson D, et al. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models. Clin Cancer Res. 2005 Apr 15;11(8):3045-54.

Tel:781-999-4286 E-mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481